Logo

Cergentis: Joris Schuurmans, Dirk Pollet, Maja Sanders

Jun 29, 2020

Cergentis of Utrecht, the Netherlands, this week announced a number of new appointments. Joris Schuurmans has become the firm's CEO, replacing Jan Dekker. Schuurmans joins Cergentis from Skyline Dx, where he led the melanoma program. Previously, he held senior executive positions at Biocartis and at MyCartis.

Further, Dirk Pollet and Maja Sanders have joined the company's supervisory board. Pollet is CEO of Enzyre and is the former CEO of Multiplicom, which was acquired by Agilent Technologies. Sanders holds supervisory roles at various organizations and has managerial experience in the private equity industry.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.